SCHEMBL24665397

SCHEMBL24665397

N[C@H](CO)Cc1nc(-c2cccc(Oc3ccc(-c4ccn[nH]4)cn3)c2)no1

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 20/20 0.82
▸ KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27204766 1.00 LTA4H (0.82) LTA4HKCNH2
SCHEMBL30006015 1.00 LTA4H (0.82) LTA4HKCNH2
SCHEMBL29123414 0.90 LTA4H (1.00) LTA4HKCNH2
SCHEMBL30005816 0.90 LTA4H (1.00) LTA4HKCNH2
SCHEMBL24665344 0.90 LTA4H (1.00) LTA4HKCNH2
SCHEMBL29123435 0.87 LTA4H (0.63) LTA4H
SCHEMBL29123438 0.87 LTA4H (0.63) LTA4H
SCHEMBL27204644 0.86 LTA4H (0.61) LTA4H
SCHEMBL27171422 0.86 LTA4H (0.61) LTA4H
SCHEMBL24665357 0.83 LTA4H (0.58) LTA4HKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4628163-A1 NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES Novartis AG (CH) 2025-10-08 — — EP disclosed
EP-4323062-B1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2025-07-23 — — EP disclosed
US-20240199593-A1 Novel Heteroaryl Aminopropanol Derivatives NOVARTIS PHARMA AG (CH) 2024-06-20 — — US disclosed
US-11932630-B2 Heteroaryl aminopropanol derivatives NOVARTIS AG (CH) 2024-03-19 — — US disclosed
CN-117015537-A Heteroaryl aminopropanol derivatives as inhibitors of LTA4H 诺华股份有限公司 2023-11-07 — — CN disclosed
US-20220348566-A1 Novel Heteroaryl Aminopropanol Derivatives NOVARTIS AG (CH) 2022-11-03 — — US disclosed
WO-2022219546-A1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2022-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348566-A1 Novel Heteroaryl Aminopropanol Derivatives CYP11B2, CYP11B1, CYP3A43 LTA4H 953/4885KCNH2 1671/4885
US-20240199593-A1 Novel Heteroaryl Aminopropanol Derivatives CYP3A43, CYP3A5, CYP51A1 LTA4H 1384/4885KCNH2 3303/4885
US-11932630-B2 Heteroaryl aminopropanol derivatives CYP3A43, CYP11B2, ADRB3 LTA4H 1006/4885KCNH2 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback